Liao Zhuangyao, Li Ming, Wen Guoming, Wang Kun, Yao Dengbo, Chen Enming, Liang Yuwei, Xing Tong, Su Kaihui, Liang Changchun, Che Zhen, Ning Qing, Tang Jun, Yan Wenbin, Li Yuxi, Huang Lin
Department of Orthopedics, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
NPJ Precis Oncol. 2023 Jun 29;7(1):62. doi: 10.1038/s41698-023-00415-7.
Postoperative recurrence and metastasis are the main reasons for the poor prognosis of osteosarcoma (OS). Currently, an ideal predictor for not only prognosis but also drug sensitivity and immunotherapy responses in OS patients is urgently needed. Angiogenesis plays a crucial role in tumour progression, which suggests its immense potential for predicting prognosis and responses to immunotherapy for OS. Angiogenesis patterns in OS were explored in depth in this study to construct a prognostic model called ANGscore and clarify the underlying mechanism involved in the immune microenvironment. The efficacy and robustness of the model were validated in multiple datasets, including bulk RNA-seq datasets (TARGET-OS, GSE21257), a single-cell RNA-seq dataset (GSE152048) and immunotherapy-related datasets (GSE91061, GSE173839). OS patients with a high ANGscore had a worse prognosis, accompanied by the immune desert phenotype. Pseudotime and cellular communication analyses in scRNA-seq data revealed that as the ANGscore increased, the malignant degree of cells increased, and IFN-γ signalling was involved in tumour progression and regulation of the tumour immune microenvironment. Furthermore, the ANGscore was associated with immune cell infiltration and the response rate to immunotherapy. OS patients with high ANGscore might be resistant to uprosertib, and be sensitive to VE821, AZD6738 and BMS.345541. In conclusion, we established a novel ANGscore system by comprehensively analysing the expression pattern of angiogenesis genes, which can accurately differentiate the prognosis and immune characteristics of OS populations. Additionally, the ANGscore can be used for patient stratification during immunotherapy, and guide individualized treatment strategies.
术后复发和转移是骨肉瘤(OS)预后不良的主要原因。目前,迫切需要一种不仅能预测骨肉瘤患者预后,还能预测其药物敏感性和免疫治疗反应的理想指标。血管生成在肿瘤进展中起着关键作用,这表明其在预测骨肉瘤预后和免疫治疗反应方面具有巨大潜力。本研究深入探讨了骨肉瘤中的血管生成模式,构建了一个名为ANGscore的预后模型,并阐明了免疫微环境中潜在的机制。该模型的有效性和稳健性在多个数据集中得到了验证,包括批量RNA测序数据集(TARGET-OS、GSE21257)、单细胞RNA测序数据集(GSE152048)和免疫治疗相关数据集(GSE91061、GSE173839)。ANGscore高的骨肉瘤患者预后较差,伴有免疫沙漠表型。对scRNA-seq数据进行的拟时间和细胞通讯分析表明,随着ANGscore的增加,细胞的恶性程度增加,且IFN-γ信号通路参与肿瘤进展和肿瘤免疫微环境的调节。此外,ANGscore与免疫细胞浸润和免疫治疗反应率相关。ANGscore高的骨肉瘤患者可能对uprosertib耐药,而对VE821、AZD6738和BMS.345541敏感。总之,我们通过综合分析血管生成基因的表达模式建立了一种新型的ANGscore系统,该系统能够准确区分骨肉瘤人群的预后和免疫特征。此外,ANGscore可用于免疫治疗期间的患者分层,并指导个体化治疗策略。